Lumida
/LMAT
⌘K
LeMaitre Vascular Inc

LeMaitre Vascular Inc

LMAT
$80.59USD+2.27%+1.79 today

MARKET CAP

1.8B

P/E (TTM)

29.7x

FWD P/E

DAY RANGE

$79 – $81

52W RANGE

$78
$118

AI Summary

Stalk
StalkMedium

LMAT is in a Stage 3 base with a Post-Capitulation pattern and oversold context suggesting a medium-term mean-reversion bounce. However, price trades below the short EMAs and lacks clear upward momentum, so execution is deferred. Stalk for a reclaim and acceptance above the 9-EMA and 20-EMA within the consolidation zone near recent lows before committing.

  • 10% organic sales growth in Q2 2026 driven by price hikes and unit sales
  • Artograph revenue projected to rise from $4M in 2025 to $11M in 2026
  • Q2 EPS $0.74 missed analyst $0.81 estimate amid export headwinds
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$154.4M$161.7M$193.5M$219.9M$249.6M
YoY %+19.4%+4.7%+19.7%+13.6%+13.5%
P / Sales7.0x6.2x6.6x9.5x7.5x
EV / Sales7.1x6.4x6.7x10.4x8.2x
Gross Profit, Adj.$101.4M$104.9M$127.0M$150.9M$178.5M
YoY %+19.8%+3.5%+21.1%+18.8%+18.3%
Margin %65.7%64.9%65.7%68.6%71.5%
EV / Gross Profit10.9x9.8x10.2x15.2x11.5x
EBITDA, Adj.$47.5M$39.4M$46.7M$61.9M$78.3M
YoY %+29.4%-17.1%+18.7%+32.4%+26.6%
Margin %30.8%24.4%24.1%28.1%31.4%
EV / EBITDA23.2x26.2x27.7x37.0x26.2x
EBIT$36.4M$26.8M$36.7M$52.3M$67.9M
YoY %+28.6%-26.3%+36.8%+42.3%+30.0%
Margin %23.6%16.6%19.0%23.8%27.2%
EV / EBIT30.3x38.4x35.3x43.8x30.2x
Net Income$26.9M$20.6M$30.1M$44.0M$57.7M
YoY %+26.8%-23.3%+45.9%+46.3%+31.1%
Net Margin17.4%12.8%15.6%20.0%23.1%
EPS (GAAP)$1.25$0.93$1.34$1.93$2.52
YoY %+20.2%-25.6%+44.1%+44.0%+30.6%